|
Hokkaido University Collection of Scholarly and Academic Papers >
Graduate School of Medicine / Faculty of Medicine >
Peer-reviewed Journal Articles, etc >
Degludec is superior to glargine in terms of daily glycemic variability in people with type 1 diabetes mellitus
| Title: | Degludec is superior to glargine in terms of daily glycemic variability in people with type 1 diabetes mellitus |
| Authors: | Yamamoto, Chiho Browse this author | | Miyoshi, Hideaki Browse this author →KAKEN DB | | Fujiwara, Yutaka Browse this author | | Kameda, Reina Browse this author | | Ichiyama, Mei Browse this author | | Nomoto, Hiroshi Browse this author | | Kameda, Hiraku Browse this author | | Nakamura, Akinobu Browse this author →KAKEN DB | | Atsumi, Tatsuya Browse this author →KAKEN DB |
| Keywords: | Continuous glucose monitoring | | Insulin degludec | | Type1 diabetes mellitus |
| Issue Date: | Jan-2016 |
| Publisher: | The Japan Endocrine Society |
| Journal Title: | Endocrine Journal |
| Volume: | 63 |
| Issue: | 1 |
| Start Page: | 53 |
| End Page: | 60 |
| Publisher DOI: | 10.1507/endocrj.EJ15-0438 |
| PMID: | 26522272 |
| Abstract: | To investigate the differences in glycemic variability between the long-acting insulins glargine and degludec using continuous glucose monitoring, we conducted an open-label, multicenter, prospective, observational study that enrolled 21 participants with type 1 diabetes mellitus currently receiving basal-bolus insulin therapy with glargine. To avoid the potential influence of diet and exercise on glycemic control, all participants were housed and monitored within the hospital for the duration of the study. Once glycemic control was achieved with glargine, glycemic variability was evaluated using continuous glucose monitoring for 3 days. Glargine was then replaced by degludec and glycemic variability again assessed via continuous glucose monitoring. The primary outcome measure of mean amplitude of glycemic excursions was significantly reduced with degludec (p = 0.028), as was area under the curve for daily blood glucose level <70 mg/dL (p = 0.046). The required insulin dose was reduced up to 25% in the degludec group, although 24-h mean glucose concentrations were not different between groups. In conclusion, once or twice daily glargine was successfully replaced by a daily injection of degludec. When replacing glargine with degludec, a lower dose should be utilized to avoid hypoglycemia. Degludec is an effective and promising long-acting insulin that reduced hypoglycemia and daily blood glucose variability in participants with type 1 diabetes. |
| Type: | article |
| URI: | http://hdl.handle.net/2115/68408 |
| Appears in Collections: | 医学院・医学研究院 (Graduate School of Medicine / Faculty of Medicine) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)
|
Submitter: 三好 秀明
|
